267 related articles for article (PubMed ID: 17707638)
1. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
Dummer R; Assaf C; Bagot M; Gniadecki R; Hauschild A; Knobler R; Ranki A; Stadler R; Whittaker S
Eur J Cancer; 2007 Nov; 43(16):2321-9. PubMed ID: 17707638
[TBL] [Abstract][Full Text] [Related]
2. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
3. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
4. Current management strategies for cutaneous T-cell lymphoma.
Knobler E
Clin Dermatol; 2004; 22(3):197-208. PubMed ID: 15262305
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin AG
J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cutaneous T-cell lymphoma.
Zackheim HS
Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
10. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
[No Abstract] [Full Text] [Related]
11. Update on treatment of cutaneous T-cell lymphoma.
Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment in CTCL: the current role of bexarotene.
Delfino C; Grandi V; Pileri A; Rupoli S; Quaglino P; Alterini R; Goteri G; Canafoglia L; Pimpinelli N
G Ital Dermatol Venereol; 2012 Dec; 147(6):573-80. PubMed ID: 23149703
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of cutaneous T-cell lymphomas].
Rappersberger K; Ortel B; Forstinger C; Wolff K
Wien Klin Wochenschr; 1994; 106(10):300-8. PubMed ID: 8053197
[TBL] [Abstract][Full Text] [Related]
14. The role of maintenance phototherapy in cutaneous T-cell lymphoma.
Pothiawala SZ; Baldwin BT; Cherpelis BS; Glass LF; Fenske NA
J Drugs Dermatol; 2010 Jul; 9(7):800-3. PubMed ID: 20677536
[TBL] [Abstract][Full Text] [Related]
15. Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement.
Ardigò M; Marulli GC; Cota C; Mastroianni A; Berardesca E
J Drugs Dermatol; 2007 Feb; 6(2):216-9. PubMed ID: 17373182
[TBL] [Abstract][Full Text] [Related]
16. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
17. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
18. The role of phototherapy in cutaneous T-cell lymphoma.
Pothiawala SZ; Baldwin BT; Cherpelis BS; Lien MH; Fenske NA
J Drugs Dermatol; 2010 Jul; 9(7):764-72. PubMed ID: 20677530
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
20. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]